



AMURA

Press Release

Amura announces single-crystal XRD confirmation for key AMcore™ intermediate in its autoimmunity programmes

Cambridge, U.K. – 10th November 2008

Amura Holdings Limited ("Amura") today announced proof of absolute stereochemistry of a pivotal AMcore™ chiral intermediate used for the synthesis of lead compounds in their autoimmunity programmes. The data provides on-going validation towards full large scale preparation of homochiral active pharmaceutical ingredients (API's) ready for IND candidate nomination as potential new treatments for autoimmune diseases. The single-crystal X-ray structure determination (XRD) was resolved through SAFC Pharma™ at their world-leading Pharmorphix® solid form research services centre. The results further support development of these compounds towards pre-IND candidate selection and subsequent progression to the clinic.

Amura's lead compounds for their autoimmunity programmes are derived from the proprietary AMcore™ scaffold, which provides a turnkey solution for inhibitor design against cysteine peptidases of the CAC1 family. Cysteine peptidases are involved in several diseases and the AMcore™ scaffold provides a powerful platform for discovery of drugs with potential utility against a range of commercially attractive therapeutic targets. The company has programmes selectively targeting cathepsin K, cathepsin S and other members of this family.

Amura intends to out-license its AMcore™ candidate compounds for clinical development.

Additional information about Amura is available at the company website: <http://www.amura.co.uk/>

Additional information about Pharmorphix® is available at: <http://www.safc-pharmorphix.com>

Contact:

Manoj Ramjee
Amura Therapeutics Limited

☎ +44 (0)1223 839797

☎ +44 (0)1223 839898

✉ manoj.ramjee@amura.co.uk